drugset / Trial / NCT00665639

Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis

NCT00665639

Phase 3 Completed 454 enrolled Astellas Pharma Inc
RandomizedParallel-groupTriple-blindTreatment

Summary

To determine the efficacy and safety of daily doses of IV micafungin versus IV caspofungin for the treatment of esophageal candidiasis

Timeline

Start
2004-06
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Caspofungin Other / unclassified
Subject Micafungin Peptide

Indications